ProfileGDS5678 / 1429191_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 71% 69% 71% 73% 64% 71% 73% 71% 71% 71% 71% 73% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0889367
GSM967853U87-EV human glioblastoma xenograft - Control 24.4416871
GSM967854U87-EV human glioblastoma xenograft - Control 34.260969
GSM967855U87-EV human glioblastoma xenograft - Control 44.5555371
GSM967856U87-EV human glioblastoma xenograft - Control 54.7402473
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8708364
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4861571
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.7406673
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.4387571
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.4718171
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4538371
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.4904471
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.7100573
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4809471